THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...
Almost all (95%) Medicare drug plans cover Repatha. This includes standalone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Repatha is a brand ...
The US Food and Drug Administration (FDA) has approved Amgen's cholesterol-lowering medication, Repatha (evolocumab) injection, a human monoclonal antibody that inhibits proprotein convertase ...
Amgen still hopes new cardiovascular data will solve a problem facing cholesterol drug, Repatha – in almost eight out of ten cases US insurers and Medicare initially refuse to prescribe the drug. One ...
Most stand-alone Medicare Part D prescription drug plans and Medicare Advantage plans that include drug coverage cover Repatha, an injectable medication for high cholesterol and cardiovascular disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results